Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About MCB
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Molecular and Cellular Biology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About MCB
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
CELL GROWTH AND DEVELOPMENT

Insulin-Like Growth Factor-Mediated Muscle Cell Survival: Central Roles for Akt and Cyclin-Dependent Kinase Inhibitor p21

Margaret A. Lawlor, Peter Rotwein
Margaret A. Lawlor
Molecular Medicine Division, Oregon Health Sciences University, Portland, Oregon 97201-3098
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Rotwein
Molecular Medicine Division, Oregon Health Sciences University, Portland, Oregon 97201-3098
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/MCB.20.23.8983-8995.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

    • Open in new tab
    • Download powerpoint
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    IGF-I and PDGF maintain myoblast survival, but only IGF-I promotes differentiation. (A) Cell counts (expressed as the percentage at time zero [T0]) of C2AS12 myoblasts after a 24- or 48-h incubation in DM with or without R3IGF-I (2 nM) or PDGF-BB (0.4 nM). The asterisk indicates that significantly fewer cells survived (P < 0.0006) in untreated than in growth factor-treated cells. Results are means ± SEMs from three experiments, each performed in duplicate. (B) IGF-I induces muscle differentiation. Results of immunocytochemical staining for myogenin and MHC after incubation of C2AS12 myoblasts in DM with PDGF-BB or R3IGF-I for 24 to 72 h are shown.

    • Open in new tab
    • Download powerpoint
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Treatment with IGF-I stimulates expression of p21. (A) The autoradiograph shows results of a representative RNase protection assay performed using total RNA isolated from C2AS12 cells incubated with either R3IGF-I (2 nM) or PDGF-BB (0.4 nM) for the indicated times. The numbers below each panel correspond to the change in mRNA abundance relative to that at time zero. The bottom panel shows a photograph of an ethidium bromide-stained gel of the RNA used in these studies. Similar results were seen in three independent experiments. (B) The upper panel shows a representative immunoblot using an antibody to p21 and whole-cell protein extracts from C2AS12 cells incubated with either R3IGF-I (2 nM) or PDGF-BB (0.4 nM) for the indicated times. The numbers below each panel correspond to the change in protein abundance relative to that at time zero. Similar results were seen in seven independent experiments. The lower panel shows the same blot after being stripped and incubated with an antibody to CDK-4. (C) Representative fluorescence micrographs of C2AS12 myoblasts treated with either R3IGF-I (2 nM) or PDGF (0.4 nM) for 24 h as described in Materials and Methods and stained with anti-p21 antibody (A and B) or Hoechst dye (C and D). Panels E and F are merged images of panels A and C and panels B and D, respectively.

  • Fig. 3.
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Forced expression of p21 stimulates myoblast survival. C2AS12 cells were transfected with the p21-IRES-EGFP expression plasmid shown above the graph, or with EGFP alone, as described in Materials and Methods. Cell counts of transfected myoblasts were performed after a 24- or 48-h incubation in DM or in DM supplemented with R3IGF-I (2 nM). Results are presented as means ± SEMs from four experiments, each performed in duplicate. The asterisks indicate that survival was significantly less in myoblasts transfected with EGFP than in p21-transfected or IGF-I-treated cells (∗, P < 0.001, ∗∗, P < 0.003). CMV/EP, enhancer-promoter from cytomegalovirus.

  • Fig. 4.
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Inhibition of p21 expression prevents IGF-stimulated myoblast survival. (A) Expression of a p21AS cDNA blocks IGF-induced accumulation of p21 protein. C2AS12 cells were transiently cotransfected with the p21AS-IRES-EGFP and EGFP expression plasmids, as described in Materials and Methods. Cells were then incubated in DM plus R3IGF-I (2 nM) for 24 h. The top panels show photomicrographs of a group of cells (magnification, ×400). The left panel shows expression of EGFP, and the center panel shows results of immunostaining for p21. In the right panel merged EGFP and p21 images are displayed. Below the micrographs results are presented as the percentage of cells transfected with either the p21AS-IRES-EGFP or IRES-EGFP expression plasmid that also express p21 protein (means ± SEMs from three experiments, counting 100 cells per experiment; ∗, P < 0.0001). (B) Inhibition of p21 blocks IGF-mediated myoblast survival. C2AS12 cells were transiently transfected with the p21AS-IRES-EGFP expression plasmid. Cell counts of transfected myoblasts were performed at 24 and 48 h after incubation in DM or in DM supplemented with R3IGF-I (2 nM) or PDGF-BB (0.4 nM). Results are presented as the means ± SEMs from three independent experiments, each performed in duplicate. The symbols indicate that survival was significantly less in myoblasts transfected with p21AS and treated with DM or R3IGF-I than in cells transfected with p21AS and incubated with PDGF-BB at 24 h (∗, P < 0.01; ∗∗, P < 0.03) or at 48 h (#, P < 0.02; ##, P < 0.001).

  • Fig. 5.
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Akt induces p21 expression. (Top panels) Representative fluorescence micrographs of C2AS12 muscle cells transiently transfected with the iAkt-IRES-EGFP expression plasmid, as described in Materials and Methods. Following a 24-h incubation in DM alone (A and C) or in DM containing HT (1 μM) (B and D), expression of iAkt was assessed by immunostaining using an anti-HA (α-HA) primary antibody and a fluorescein-labeled secondary antibody (A and B). Expression of p21 (C and D) also was determined by immunofluorescence. (Bottom panel) The graph shows quantitation of p21 expression in cells transfected with the iAkt-IRES-EGFP plasmid following treatment with DM alone or containing HT (means ± SEMs from three experiments, counting 100 cells per experiment; ∗, P < 0.003).

  • Fig. 6.
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    IGF-I treatment does not cause nuclear translocation of the NF-κB subunit p65 Rel A. (A to C) Representative fluorescence micrographs of C2AS12 myoblasts incubated in DM without or with either R3IGF-I (2 nM) or tumor necrosis factor alpha (1.2 nM) for 2 h and immunostained with an antibody to p65 Rel A. (D to F) Same cells as in panels A to C stained with Hoechst dye.

  • Fig. 7.
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Inhibition of p21 expression blocks Akt-mediated myoblast survival. (A) C2AS12 cells were transiently cotransfected with iAkt-IRES-EGFP and either the p21AS-IRES-EGFP or EGFP expression plasmid, as described in Materials and Methods. Cell counts of transfected myoblasts were performed 24 h after incubation in DM or in DM plus HT (1 μM). Results are presented as the means ± SEMs from three independent experiments, each performed in duplicate. Survival was significantly greater in HT-treated cells cotransfected with EGFP than with p21AS (∗, P < 0.003). (B) Inhibition of p21 expression does not block induction of Akt kinase activity. Results are of in vitro kinase assays for Akt using immunoprecipitates from cells cotransfected with the iAkt-IRES-EGFP and p21AS-IRES-EGFP expression plasmids and incubated without or with HT for 4 h are shown. Results from a representative experiment are pictured in the top panel. Results of three independent experiments (means ± SEMs) are plotted in the bottom panel. Values on the y axis represent arbitrary densitometric units. Significantly more Akt enzymatic activity could be measured after treatment with HT (∗, P < 0.003).

  • Fig. 8.
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    IGF-I cannot maintain survival in the absence of p21 expression. C2AS12 cells were transiently cotransfected with p21AS-IRES-EGFP and iAkt-IRES-EGFP expression plasmids, as described in Materials and Methods. Cell counts of transfected myoblasts were performed 24 h after incubation in DM or in DM supplemented with R3IGF-I (2 nM) or PDGF-BB (0.4 nM). Results are presented as the means ± SEMs from three independent experiments, each performed in duplicate. The asterisks indicate that survival was significantly less in transfected myoblasts treated with IGF-I than in cells incubated with PDGF (P < 0.01).

  • Fig. 9.
    • Open in new tab
    • Download powerpoint
    Fig. 9.

    Inhibition of p21 expression blocks muscle cell survival. C2 or L6 myoblasts were transiently transfected with the p21AS-IRES-EGFP or EGFP expression plasmid. Cell counts of transfected myoblasts were performed at 24 and 48 h after incubation in DM. Results are presented as the means ± SEMs from three independent experiments, each performed in duplicate. The asterisks indicate that survival was significantly less in myoblasts transfected with p21AS-IRES-EGFP than in cells transfected with EGFP at either time point (∗, P < 0.01; ∗∗, P < 0.03).

PreviousNext
Back to top
Download PDF
Citation Tools
Insulin-Like Growth Factor-Mediated Muscle Cell Survival: Central Roles for Akt and Cyclin-Dependent Kinase Inhibitor p21
Margaret A. Lawlor, Peter Rotwein
Molecular and Cellular Biology Dec 2000, 20 (23) 8983-8995; DOI: 10.1128/MCB.20.23.8983-8995.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Molecular and Cellular Biology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Insulin-Like Growth Factor-Mediated Muscle Cell Survival: Central Roles for Akt and Cyclin-Dependent Kinase Inhibitor p21
(Your Name) has forwarded a page to you from Molecular and Cellular Biology
(Your Name) thought you would be interested in this article in Molecular and Cellular Biology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Insulin-Like Growth Factor-Mediated Muscle Cell Survival: Central Roles for Akt and Cyclin-Dependent Kinase Inhibitor p21
Margaret A. Lawlor, Peter Rotwein
Molecular and Cellular Biology Dec 2000, 20 (23) 8983-8995; DOI: 10.1128/MCB.20.23.8983-8995.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

cyclins
Insulin-Like Growth Factor I
Insulin-Like Growth Factor II
Muscle, Skeletal
Protein-Serine-Threonine Kinases
Proto-Oncogene Proteins

Related Articles

Cited By...

About

  • About MCB
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #MCBJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0270-7306; Online ISSN: 1098-5549